SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-005199
Filing Date
2023-02-15
Accepted
2023-02-15 16:00:33
Documents
14
Period of Report
2023-02-09
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 65838
2 ex3-1.htm EX-3.1 18377
  Complete submission text file 0001493152-23-005199.txt   308028

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE bct-20230209.xsd EX-101.SCH 3949
4 XBRL DEFINITION FILE bct-20230209_def.xml EX-101.DEF 26582
5 XBRL LABEL FILE bct-20230209_lab.xml EX-101.LAB 36619
6 XBRL PRESENTATION FILE bct-20230209_pre.xml EX-101.PRE 25206
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5539
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 001-40101 | Film No.: 23635309
SIC: 2834 Pharmaceutical Preparations